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inhibitors in Norway. Pharmacoeconomic analyses also show that large financial
resources would be saved if the structure of the utilized ACE inhibitors in Serbia
were more similar to the one in Norway.
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OBJECTIVES: Around 800,000 patients are diagnosed for atrial fibrillation (AF) in
France with an increased risk of strokes. For many of them, prevention with anti-
coagulant is managed in primary care. Prevention should be driven by individual
risk for stroke estimated with a score (CHADS2) ranging from 0 (lower risk) to 6
(higher risk). This study was to describe AF patients’ management by general prac-
titioners (GP). METHODS: This cross-sectional study analyzed a medical files and
prescriptions database of a representative sample of 1,200 GPs. Data from all pa-
tients present in the database from July-2010 to June-2011, with a diagnosis of AF
and aged 18 and above were extracted. Based on age (75), comorbidities (HTA/
Diabetes) and history of stroke/TIA/CHF, CHADS2 was calculated for all patients.
Under-treatment status was defined according European guidelines which recom-
mend prevention with aspirin or vitamin-K antagonists (VKA) for CHADS21 and
VKA for CHADS22. RESULTS: A total of 15,623 AF patients were identified. Mean
age was 74.6(11.1) years old, 59.5% were men and mean CHADS2 was 1.5(1.1).
12,985 patients (83.1%) were found eligible for stroke prevention (i.e.CHADS21).
Among them, 23.4% received no prevention at all, 11.4% were under-treated (i.e.
aspirin instead of VKA) and 4.7% received non-recommended treatment (i.e. clopi-
dogrel). Within patients with CHADS21 (n5,026), 26.7% had no treatment, 48.9%,
20.5% and 3.9% were treated with VKA, aspirin and clopidogrel, respectively.
Within those with CHADS2 (n7,959), only 54.9% received VKA when 21.3% had
no treatment and 18.6% and 5.1% were prescribed aspirin and clopidogrel,
respectively. CONCLUSIONS: In this large study in French primary care, four out of
five (83.1%) of patients diagnosed with AF should benefit from stroke prevention.
Overall, around 45% of thromboembolic high-risk patients (i.e.CHADS22) were
not treated or inadequately treated. Future analyses should be performed to inves-
tigate the gap between clinical practice and guidelines.
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OBJECTIVES: The risk of cardiovascular disease (CVD) is reported to be 2-4 times
higher in patients with type 2 diabetes mellitus (T2DM). CVD is the major cause of
morbidity and mortality for diabetics and contributes most to the costs of diabetes.
This study was conducted to assess the prevalence of risk factors and cardiovas-
cular risk in newly diagnosed T2DM patients. METHODS: This was a prospective,
observational, questionnaire based study conducted in a tertiary care hospital.
Only newly diagnosed T2DM patients (duration of diabetes  6 months) were re-
cruited. Risk factors related to CVD in these patients were identified and the 10 year
cardiovascular risk was estimated using Framingham risk equation. RESULTS: The
results are based on a total of 152 newly diagnosed T2DM patients. The major
modifiable risk factors were identified as obesity (59%), hypertension (36%), dyslip-
idemia (26%) and overweight (24%). The prevalence of various microvascular and
macrovascular complications at the time of diagnosis was also assessed; 26% pa-
tients were found to have neuropathy followed by nephropathy in 7%. Only 5%
patients were diagnosed with coronary artery disease (CAD) along with T2DM. The
10 year CVD risk estimation showed that the females were at higher risk compared
to males (10 vs 6%). Further, the association of the cardiovascular risk with the risk
factors was analysed using binary logistic regression. The risk was found to be
significantly associated with age (55 vs 55 years) with an odds ratio of 3.38 (95%
CI 1.14-10.02; P0.03). CONCLUSIONS: The prevalence of risk factors for CVD in
newly diagnosed T2DM patients was found to be high; however, the estimated risk
was low according to the Framingham risk scoring system. Therefore, the authors
suggest that timely management of these risk factors is needed to reduce the
occurrence of CVD.
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OBJECTIVES: It is well-known that cardiovascular risk is higher in diabetes patients
but real-life country level data are scarce. The aim of this study was to compare the
cardiovascular event rate and relevant outcomes in patients with and without
diabetes in Belgium. METHODS: Event rates, average length of stay (LOS) and mor-
tality among hospitalized patients were estimated using the longitudinal IMS Hos-
pital Disease Database (2007), including data on 34.3% of Belgian hospital beds,
combined with Belgian population data. Stays were identified based on ICD-9 or
DRG coding. Acute coronary syndromes (ACS) included Myocardial infarction (ICD-
9:410-411.89) and unstable angina (ICD-9:411.1-411.8-413.0). Cerebrovascular dis-
ease (CVD) was defined as stroke (APR-DRG:045;046) and Transient Ischemic Attack
(DRG:047). Confidence intervals around relative risks (RR) were calculated to com-
pare proportions and LOS using a Wilcoxon non-parametrical test. RESULTS: In
2007 there were 10.5 million inhabitants including 450,000 diabetics. The incidence
of first ACS was 5 times higher in diabetes patients (7.7 per 1000 inhabitants vs. 1.5;
RR 5.04 [4.86-5.23]). Average LOS in diabetic ACS patients was 3 days longer (10.8 vs.
7.2 days; p0.001) and mortality during hospitalization was 38% higher (10.79% vs.
7.84%; RR 1.38 [1.14-1.66]). Recurrence within a calendar year of ACS occurred in
27% of the diabetic patients vs. 21% of the non-diabetics (RR 1.28 [1.20-1.36]). The
CVD incidence was 11.3 per 1000 inhabitants in diabetics and 2.1 per 1000 in non-
diabetics (RR: 5.26 [5.10-5.42]). In diabetic patients LOS was 4 days longer (18.5 vs.
14.5 days;p0.001), mortality during hospitalization slightly higher (9.47% vs.
8.78%; RR 1.08 [0.94-1.24]) as well as recurrence (5.11% vs. 4.62%, RR 1.11 [0.99-1.23]).
CONCLUSIONS: Patients with diabetes do not only have a significantly higher risk
of ACS and CVD, they also stay longer in the hospital, and in ACS have a signifi-
cantly higher in-hospital mortality and recurrence.
CARDIOVASCULAR DISORDERS - Cost Studies
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OBJECTIVES: Turkey pharmaceutical market is a growing market in spite of gov-
ernment policies. Public pharmaceutical market rise from 7.9 billion TL to 15.5
billion TL from 2000 to 2009. In addition, Cardiovascular system medicines market
rise from 1.3 billion TL to 1.8 billion TL from 2005 to 2010. It was reported that statin
market was 21% of the cardiovascular system medicines expenditures. Statins
have the same effectiveness and safety profile. So each statin may use instead of
others. Internal reference pricing may use for statins in Turkey. The aim of the
study is to calculate possible budget impact of jumbo basket application for statins
in Turkey. METHODS: Statin consumption for year 2010 was taken from IMS. Pos-
sible 4 different budget scenarios were calculated. Scenario A defined as reimburse
all statins with the minimum statin price. Scenario B defined as reimburse all
stations up to 15% of minimum statin price. Scenario C defined as reimburse all
statins up to 10% of average price of statins. Scenario D defined as reimburse all
statins as the calculation  (average price  minimum price)/2. RESULTS: Statin
expenditure was 496 million TL in 2010. If Scenario A or B may be used, the new
statin expenditure may be 85 million or 97 million TL, respectively. If Scenario C or
D may be used, the new statin expenditure may be 320 million TL or 308 million TL,
respectively. CONCLUSIONS: However, Scenario A or B may offer maximum de-
crease in statin budget, industry may not run business under the situation. Sce-
nario C or D may be acceptable for the industry and offer government 37% or 35%
extra decrease in statin expenditure. This pilot study may spotlight possible op-
portunities in the controlling statin market budget for government.
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OBJECTIVES: Plasmid pCMV-VEGF165 is new injectable factor, activating therapeu-
tic angiogenesis in the ischemic limb and facilitating reduction of amputation rate
in Critical limb ischemia (CLI), especially in patients who cannot undergo recon-
structive arterial surgery. pCMV-VEGF165 was recently approved for use in Russia
and not yet included in government reimbursement list, therefore suitable patients
with CLI do not have general access to it. A budget impact analysis would provide
evidence to assist budget holders in decision making processes. METHODS: A bud-
get impact model was built to allow assessment of the budgetary impact to the
Federal state budget from health care system perspective if pCMV-VEGF165 is in-
troduced into state reimbursement system in 2-year time horizon. The scenarios
adopted were world (standard treatment of CLI) with and without pCMV-VEGF165.
A cohort of 26 812 patients with unreconstructable CLI was used as population
according to epidemiology data in Russian Federation. As efficacy criteria was used
amputation rates for both scenarios obtained from published sources. Direct costs
were valued in the perspective of the Russian health care system and included
diagnostics, patients routine management and pharmacotherapy. RESULTS: Ac-
cess to all patients with unreconstructable CLI pCMV-VEGF165 was resulted in
prevention of 13 674 ischemic limb amputation over a 2-year period and the budget
impact of using to new treatment option with standard treatment in patients with
unreconstructable CLI was $45 388 392. Sensitivity analysis preformed suggested
that cost of limb amputation is the most influential variable. CONCLUSIONS: Re-
sults of the present budget impact analysis suggest that introducing of pCMV-
VEGF165 into the CLI therapeutic management would significantly decrease num-
ber of limb amputations, resulting in savings in the health care budget.
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OBJECTIVES: To estimate the effectiveness of using a simple risk score comprising
only non-biochemical parameters to identify individuals more likely to incur
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higher medical costs in six European settings. METHODS: The Archimedes model
was used to simulate cohorts of individuals ages 40 to 75 with no prior history of
diabetes, cardiovascular disease, or chronic kidney disease, in Denmark, France,
Germany, Italy, Poland and the UK. Individuals were simulated for 10 years and the
incidences of diabetes and MACE were tracked, along with mean total medical
costs per person. A risk score was computed for each simulated person, with base-
line data on age, gender, BMI, waist, smoking, family histories of diabetes and
cardiovascular disease, and antihypertensive usage. For each country, the sub-
populations of individuals with above median risk score (TOP50), and individuals in
the top risk score quartile (TOP25) were compared to the full cohorts. RESULTS:
Diabetes and MACE incidences were higher in the TOP50 and TOP25 subgroups, as
were total medical costs. In each country, the mean 10-year discounted medical
costs for the full cohorts vs. the TOP50 subgroups were: Denmark €8,482 (95%CI
8,027 - 8,937) vs. €11,292 (10,614 - 11,969); France €6,264 (5,917 - 6,611) vs. €8,492
(7,953 - 9,031); Germany €8,717 (8,218 - 9,217) vs. €11,974 (11,204 - 12,743); Italy €7,688
(7,273 - 8,104) vs. €10,279 (9,643 - 10,914); Poland €1,798 (1,707 - 1,888) vs. €2,418
(2,274 - 2,561); UK €4,100 (3,885 - 4,314) vs. €5,580 (5,238 - 5,921). Medical costs were
even higher in the TOP25 subgroup. CONCLUSIONS: This risk score could be an
effective tool for identifying individuals likely to incur higher health care costs due
to diabetes and MACE. Targeting individuals with such scores could make screen-
ing programs more efficient, provided validation in real-world populations.
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OBJECTIVES: Chronic heart failure (CHF) is a major health issue because of its
growing prevalence, morbimortality and associated resource consumption. Beta
blockers have been shown to be effective and cost-effective therapies for CHF. The
aim is determining what beta blocker constitutes the most efficient therapy for CHF
patients in Spain. METHODS: Systematic review of primary (clinical trials) and
secondary (meta-analyses, clinical practice guidelines and economic assessments)
evidence on beta blockers for CHF issued before May 2012. Once that efficacy of
each beta blocker was established, local drug databases were accessed in order to
estimate the updated annual cost of each therapy and daily dose in Spain.
RESULTS: Given their similar efficacy [death RR: bisoprolol: 0.66, p0.0001; meto-
prolol: 0.66, p0.0001; carvedilol: 0.65, p0.005, nebivolol: 0.88, p0.21] and safety
profiles, international clinical guidelines on Cardiology recommend bisoprolol,
metoprolol succinate, carvedilol and nebivolol as first choice therapies for CHF
(class I and level of evidence A). Annual treatment costs per patient reached 38.70€;
162.53-311.69€; 170.70€ and 188.14€ for bisoprolol, carvedilol, metoprolol succinate
and nebivolol, respectively. When hospitalization costs are considered, cost per
avoided death was 9.512€, 14.989€, 16.767€ and 50.795€ for bisoprolol, carvedilol,
metoprolol succinate and nebivolol, respectively. Results of the cost-benefit anal-
ysis indicated that only bisoprolol showed a net benefit, with an estimated annual
savings of 116.293€. Budget impact analysis yields that bisoprolol implies a saving
of 76-88% of carvedilol cost of therapy per year and patient, 77% when compared to
metoprolol succinate and 79% versus nebivolol. CONCLUSIONS: Despite the unde-
ruse of betablockers for CHF treatment, they have demonstrated to be effective and
cost-effective. Among them, bisoprolol gathers pharmacologic, legal and phar-
macoeconomic characteristics that confirm their being the most efficient beta
blocker (both in terms of cost-benefit and cost-effectiveness) for CHF patients in
Spain.
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OBJECTIVES: New anti-thrombotic strategy with recent low-molecular-weight
heparins (LMWHs) used for the prevention of symptomatic deep venous thrombo-
sis and pulmonary embolism (DVT/PE) has shown clinical and outcome benefits in
patients undergoing orthopedic surgery. The purpose of our study is to analyze the
costs of LMWHs in total knee replacement and to compare cost-effectiveness and
budget impact of bemiparin and enoxaparin addition to current treatment of such
patients in Russia. METHODS: Cost-effectiveness analysis and budget impact
model of patients with total knee replacement (n1000) is used to compare alter-
native strategies with bemiparin and enoxaparin for deep venous thrombosis and
pulmonary embolism prevention. The model calculates the budget impact of in-
hospital LMWHs drug therapy change for these patients. Only direct costs of med-
icines were considered. The prices of medications were taken from the official price
listing. Rates of main outcome were based on literature data (confirmed venous
thromboembolism 32.1% for bemiparin and 36.9% for enoxaparin). Net budget im-
pact was expressed as a difference in costs between the strategies where bemiparin
is gradually elevated versus traditionally enoxaparin prevention. The budget im-
pact is reported in terms of additional annual total costs. RESULTS: According to
the model, prevention of DVT/PE with bemiparin in total knee replacement was
dominant when compared to enoxaparin. Scenario of the introduction of bemi-
parin reduces budget costs for LMWHs drugs (in case 50% bemiparin and 50%
enoxaparin for 130.9 RUB / patient). In case of 100% bemiparin it can provide actual
DVT/PE prevention in 117 additional patients with total knee replacement.
CONCLUSIONS: Bemiparin demonstrated optimal cost-effectiveness and budget
savings compared to enoxaparin in total knee replacement. Further steps such as
including bemiparin in clinical recommendations and medical standards of care
for the patients is needed for implementing bemiparin in routine hospital practice.
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OBJECTIVES: Evidence on the use of newer antiplatelet agents and their cost im-
plications remains scarce. Previous research has shown a shorter average hospital
length of stay for prasugrel-treated patients compared to clopidogrel-treated pa-
tients. We analyzed a large geographically diverse database from the US and com-
pared cost of hospitalization for patients with acute coronary syndrome (ACS) who
have undergone percutaneous coronary intervention (PCI) and who received either
clopidogrel or prasugrel. METHODS: Using a large representative US database
maintained by PREMIER, we analyzed patient characteristics and total hospitaliza-
tion costs during the index (first) hospitalization among ACS-PCI patients treated
with clopidogrel or prasugrel between July 2009 and June 2011. Analysis included
patients treated with prasugrel who were on-label and clopidogrel-treated patients
who would have been eligible for prasugrel treatment per the label. Observed costs
were analyzed unadjusted and adjusted for baseline differences using a general-
ized linear model with a gamma distribution and log link function with propensity
score stratification. RESULTS:Data were available for 75,315 patients who received
clopidogrel and 9,483 patients who received prasugrel during their hospitalization.
The observed mean hospitalization costs (SD) for clopidogrel and prasugrel, respec-
tively, were $17,519 ($2,548) and $17,136 ($2,562). Mean costs for clopidogrel and
prasugrel recipients, respectively, were $16,937 ($2,162) and $16,664 ($2,137) for
STEMI, $17,926 ($2,747) and $17,511 ($2,849) for NSTEMI, and $17,900 ($2,665) and
$17,393 ($2,676) for UA (all comparisons, P0.001). The adjusted results showed
prasugrel-treated patients cost as much as $882 less than clopidogrel-treated pa-
tients (P0.001) during the index hospital stay. CONCLUSIONS: Prasugrel-treated
patients used fewer health care resources compared to clopidogrel-treated pa-
tients during the index hospital stay, as measured by hospital costs. Similar results
were obtained after adjusting for patient demographics and clinical characteris-
tics. The potential for unmeasured confounder bias is a limitation in this real-world
observational research.
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OBJECTIVES:The PLATO trial showed that ticagrelor reduced the risk of myocardial
infarction, stroke or death from vascular causes compared to clopidogrel (hazard
ratio 0.84, 95% CI 0.77 to 0.92) without a significant increase in major bleeding. The
objective of this analysis is to evaluate direct and indirect costs of ticagrelor versus
branded clopidogrel in patients with acute coronary syndromes (ACS) from a Rus-
sian health care perspective. METHODS: An excel based model was developed to
estimate the direct and indirect cost per treatment arm for specific CV events (non
fatal MIs, CV deaths and other deaths). Rates of non fatal myocardial infarction
(MI), CV death and death from other causes was extracted from the PLATO trial
(NCT00391872). Difference in direct medical and non-medical costs for ticagrelor vs
clopidogrel in patients was estimated using the events above. One-way sensitivity
analysis was performed. RESULTS: The result of this analysis shows that ticagrelor
is associated with reduced health care costs compared with branded clopidogrel for
one year treatment in a Russian health care setting. The incremental drug costs of
ticagrelor (- 264.46 RUB (€6.48) per patient per year) was offset by higher non drug
costs associated with fewer MI’s and deaths. Treatment with ticagrelor for one year
is associated with total cost savings of 2749.97 RUB (€67.37) per patient, the direct
cost savings was of 1260.83 (€30.89) and the indirect was 1489.13 RUB (€36.48) Sen-
sitivity analysis showed that ticagrelor remains to be cost saving compared to
branded clopidogrel as long as the ticagrelor price is less than 3520.94 RUB (€86.25)
per package while keeping other model parameters unchanged. CONCLUSIONS:
This analysis demonstrates that one year treatment with ticagrelor is less costly
than branded clopidogrel for patients with ACS from a Russian health care perspec-
tive.
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OBJECTIVES: Two approaches recanalization or restoration of adequate perfusion
and neuroprotection are identified as a pathogenic treatment of acute ischemic
stroke (AIS). Timely mechanical revascularization and thrombolytic therapy pre-
vent the development of neurons necrosis and significantly improve survival and
quality of patient life. Unfortunately, in Ukraine these methods are difficult of
access for patients due to high cost, late diagnostics and contraindications. The
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